TrialRMD open2024

Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.

M Elaine Husni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.